CN105792816A - 以基因突变为特征的癌症的预防或治疗中的tor激酶抑制剂 - Google Patents

以基因突变为特征的癌症的预防或治疗中的tor激酶抑制剂 Download PDF

Info

Publication number
CN105792816A
CN105792816A CN201480066619.0A CN201480066619A CN105792816A CN 105792816 A CN105792816 A CN 105792816A CN 201480066619 A CN201480066619 A CN 201480066619A CN 105792816 A CN105792816 A CN 105792816A
Authority
CN
China
Prior art keywords
gene
patient
cancer
variant
sudden change
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480066619.0A
Other languages
English (en)
Chinese (zh)
Inventor
徐水蟾
克里斯汀·梅·海格
吴小玲
杨志宏
康斯坦提诺斯·马夫罗马蒂斯
埃伦·菲尔瓦罗夫
史涛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signal Pharmaceuticals LLC
Original Assignee
Signal Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharmaceuticals LLC filed Critical Signal Pharmaceuticals LLC
Publication of CN105792816A publication Critical patent/CN105792816A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201480066619.0A 2013-10-04 2014-10-03 以基因突变为特征的癌症的预防或治疗中的tor激酶抑制剂 Pending CN105792816A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361886785P 2013-10-04 2013-10-04
US61/886,785 2013-10-04
US201361907510P 2013-11-22 2013-11-22
US61/907,510 2013-11-22
US201462005597P 2014-05-30 2014-05-30
US62/005,597 2014-05-30
PCT/US2014/059043 WO2015051251A1 (en) 2013-10-04 2014-10-03 A tor kinase inhibitor in the prevention or treatment of cancer characterized by gene mutations

Publications (1)

Publication Number Publication Date
CN105792816A true CN105792816A (zh) 2016-07-20

Family

ID=51869019

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480066619.0A Pending CN105792816A (zh) 2013-10-04 2014-10-03 以基因突变为特征的癌症的预防或治疗中的tor激酶抑制剂

Country Status (6)

Country Link
US (1) US20150099754A1 (enExample)
EP (1) EP3052093A1 (enExample)
JP (1) JP2016540726A (enExample)
CN (1) CN105792816A (enExample)
MX (1) MX2016004212A (enExample)
WO (1) WO2015051251A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110592213A (zh) * 2019-09-02 2019-12-20 深圳市新合生物医疗科技有限公司 预测新抗原负荷和检测基因组突变的基因panel
CN115326915A (zh) * 2022-08-01 2022-11-11 中央民族大学 一种植物组织微阵列maldi-msi高通量分析方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015160868A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Methods for treating cancer using tor kinase inhibitor combination therapy
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130102613A1 (en) * 2011-10-19 2013-04-25 Signal Pharmaceuticals, Llc Treatment of cancer with tor kinase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
NZ599549A (en) 2009-10-26 2013-11-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
WO2011112666A1 (en) * 2010-03-09 2011-09-15 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CA2856295A1 (en) * 2011-11-18 2013-05-23 Vanderbilt University Markers of triple-negative breast cancer and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130102613A1 (en) * 2011-10-19 2013-04-25 Signal Pharmaceuticals, Llc Treatment of cancer with tor kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CL ARTEAGA: "The phosphatidylinositol-3 kinase/mTOR pathway: new agents", 《BREAST CANCER RESEARCH》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110592213A (zh) * 2019-09-02 2019-12-20 深圳市新合生物医疗科技有限公司 预测新抗原负荷和检测基因组突变的基因panel
CN115326915A (zh) * 2022-08-01 2022-11-11 中央民族大学 一种植物组织微阵列maldi-msi高通量分析方法

Also Published As

Publication number Publication date
EP3052093A1 (en) 2016-08-10
JP2016540726A (ja) 2016-12-28
WO2015051251A1 (en) 2015-04-09
US20150099754A1 (en) 2015-04-09
MX2016004212A (es) 2016-07-11

Similar Documents

Publication Publication Date Title
JP7042950B2 (ja) ブルトン型チロシンキナーゼ（Ｂｔｋ）の阻害剤の使用
RU2565034C2 (ru) Идентификация мутации lkb1 в качестве прогностического биомаркера чувствительности к ингибиторам tor-киназы
JP2024037857A (ja) ファルネシルトランスフェラーゼ阻害剤を用いて癌患者を治療する方法
CA2990703A1 (en) Biomarkers for nanoparticle compositions
AU2014254052B2 (en) Treatment of cancer with dihydropyrazino-pyrazines
US9980963B2 (en) Treatment of cancer with dihydropyrazino-pyrazines
KR20210065203A (ko) 브루톤 티로신 인산화효소(btk)의 억제제의 용도
TW201733584A (zh) 以ｔｏｒ激酶抑制劑治療癌症
CN108992446A (zh) 用tor激酶抑制剂治疗癌症
EA036790B1 (ru) Способ лечения злокачественной пекомы
WO2014172424A1 (en) Treatment of cancer with dihydropyrazino-pyrazines
CN105792816A (zh) 以基因突变为特征的癌症的预防或治疗中的tor激酶抑制剂
US12268690B2 (en) Treatments for mutations in acute myeloid leukemia
TW201818965A (zh) 以法呢基轉移酶（ｆａｒｎｅｓｙｌ ｔｒａｎｓｆｅｒａｓｅ）抑制劑治療癌症病患之方法
EP2961408A1 (en) Treatment of cancer with tor kinase inhibitors
TW202521125A (zh) 治療ｒａｓ蛋白相關疾病或病症之方法
TW202502351A (zh) 治療ｒａｓ相關疾病或病症之方法
US12171829B2 (en) Abituzumab for the treatment of colorectal cancer
US20240190858A1 (en) Crystalline forms, pharmaceutical compositions and methods of use thereof
US20220226338A1 (en) Methods of Treating Cancer Using CHK1 Inhibitors
US20250319063A1 (en) Methods and compounds for restoring mutant p53 function
JP7419572B2 (ja) 小児がん治療用医薬組成物
WO2025080726A1 (en) Methods of treating conditions with mutant p53 reactivating compounds
CN118632695A (zh) 尼拉帕尼和醋酸阿比特龙加泼尼松用于改善患有转移性去势抵抗性前列腺癌和hrr改变的患者的临床结果
CN117222403A (zh) 索托拉西布制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160720